Please login to the form below

The dark side of direct-to-consumer genetic tests

Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients to unnecessary surgeries, we reveal the barriers for healthcare professionals and patients, and how to solve these industry challenges.

Today, anyone with £150 can order a genetic test from the comfort of their own home. These tests promise to unlock the secrets of consumers’ DNA, reporting on genetic health risks, carrier status, traits and ancestry.

This is the Uber of healthcare, catering to millennials’ desire for slick websites, wellness-trends, and neatly packaged information delivered at the click of a button.

However, with a recent study revealing 40% of the raw data produced in direct-to-consumer tests is incorrect, there is a question mark over how far these tests are benefiting patients or if they are clouding an already complex market.

Blue Latitude Health speaks to two experts in the field of genetic testing to learn about this issue and better understand how the industry can unite to solve these challenges.

The limitations of direct-to-consumer genetic tests

Some of the leading direct-to-consumer genetic testing companies use third-party sites to analyse data. However, this data is not always up-to-date or correct. Now new evidence has emerged showing that an “alarmingly high” 40% of raw data delivered by third parties analysing direct-to-consumer tests is incorrect.

Rather than providing a comprehensive genetic risk assessment, these tests analyse a limited set of variants, which are not necessarily causal of conditions. The tests do not consider the impact of environment and lifestyle. Instead, they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health.

While this may be clear to those with a background in genetics, the lack of public awareness around genetic science combined with the limited genetic knowledge healthcare professionals possess, provides a perfect storm of risk for patients. 

Genetics: one piece of a complex puzzel

In 2017 the FDA approved the first direct-to-consumer genetic test. However, the approval came with a caveat preventing test results being used to ascertain a consumers’ overall risk for developing a condition. Still, everyday members of the public order these tests, receive the results and visit their doctors to decipher the information, despite the disclaimers and warnings.

Who can blame them? If an email landed in your inbox that appeared to indicate you had an increased risk of cancer, Parkinson’s disease, Alzheimer’s disease, or any other potentially life-altering or life-threatening condition, you would want to confirm the results with a healthcare professional too.

Taichi Ochi is a Regional Account Manager at Macrogen, a Korean biotech and precision medicine company that specialises in next-generation sequencing. The organisation works across 153 countries. Its services range from conducting government research to providing patients and healthcare professionals with diagnostic results, offering genome studies and using genomics in forensics. To date it has completed 30 million cases of genome sequencing, making it a market expert.

For Taichi, the challenges of direct-toconsumer tests should come with a warning: “while the tests are a great asset for healthcare, it is not the bible that people should refer to when making clinical decisions. Using direct-to-consumer tests as the main source of decision making is the same as identifying the completed puzzle from a puzzle piece”

What is a variant of unknown significance (VUS)?

One of the barriers around direct-toconsumer testing is the lack of education on genetic variants held by both physicians and the general public.

“Patients are frequently confused by what a variant means. They often misunderstand and think a variant means they have got a disease-causing mutation, which isn’t right” says Vicki Kiesel, a Director at GeneHealth UK with a decade of experience in genetics. 



Download the full article from Blue Latitude Health

1st October 2018

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.
Blue Latitude Health
Innovative approaches in the treatment of multiple sclerosis
Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.
Blue Latitude Health
Q&A with Dr Timothy Vollmer, leading MS Neurologist
Blue Latitude Health sits down with key opinion leader and specialist neurologist Dr Timothy Vollmer to better understand the paradigm shift in MS treatment. He explains the challenges neurologists face when making treatment decisions, and why patients need to be treated with more efficacious drugs earlier on.
Blue Latitude Health
Living my best life with multiple sclerosis
Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can unite to improve quality of life for MS patients today, and why her diagnosis isn’t stopping her achieving her goals.
Blue Latitude Health
Creative review: ESMO 2018
BLH reviews the creative concepts exhibited at the European Society for Medical Oncology (ESMO) 2018 Congress, crowning our best booth winners and giving key insights on how to develop an inspiring design for your booth.
Blue Latitude Health
A unique tool for turning data into brand strategy
Head of Insight Martine Leroy, uses her 25+ years’ experience to develop an exclusive perceptual framework for research design and analysis, which generates a deeper understanding of customer needs and the changing market dynamics
Blue Latitude Health